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The field of diagnostic and therapeutic endoscopic ultrasound (EUS) is growing rapidly. Although EUS has enhanced our
ability to diagnose and treat a wide variety of GI conditions, there are many controversial issues regarding the appropriate
application of EUS techniques. In this review we discuss five controversial topics in EUS: the utility of EUS in staging of
esophageal and gastric cancer; selection of appropriate needle gauge for fine needle aspiration (FNA); use of the stylet in
FNA; and the emerging role of contrast agents in endoscopic ultrasound.
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INTRODUCTION
Endoscopic ultrasound (EUS) was first introduced into clin-
ical practice in the 1980s and has rapidly evolved into a
reliable technique for diagnosis of lesions of the digestive
tract. In its infancy in the 1980s, radial echoendoscopes
were used only to image lesions of the GI tract [1–4].
With the subsequent advent of fine needle aspiration
(FNA), the curved linear array echoendoscope became an
important tool for tissue diagnosis [5–6]. Recently endo-
scopic ultrasound has been used increasingly for interven-
tional endoscopy. Procedures such as EUS-guided biliary
access and drainage, fiducial placement and other
EUS-guided therapies (e.g. ethanol ablations of tumors)
have been performed [7].
Although EUS has enhanced our ability to diagnosis and
treat a wide variety of GI conditions, there are many con-
troversial issues regarding the appropriate application of
EUS techniques. The purpose of this review article is to de-
scribe some of the more common controversies and the
current literature surrounding these controversies to help
the clinician performing EUS to better understand these
issues and optimize his or her practice. We will discuss
each issue under a separate heading.
STAGING OF ESOPHAGEAL
CANCER: IS EUS NECESSARY?
According to the National Cancer Institute, the number of
estimated new cases of esophageal cancer in the United
States alone in 2012 is 17460 [8], representing the
fastest-growing prevalence of any cancer in the western
hemisphere. Prognostic and therapeutic decisions in esoph-
ageal cancer hinge on accurate tumor staging [9–10]. One
of the most common indications for endoscopic ultrasound
is esophageal cancer staging. Prognosis of esophageal
cancer is related to tumor depth staging (T stage) and
lymph node metastasis [10]. Esophageal cancer limited to
only mucosa (T1a) has less than a 5–9% chance of metasta-
sis compared with a 19–44% chance of lymph node metas-
tasis with esophageal cancer invading the submucosa (T1b)
(staging per the American Joint Committee on Cancer)
[11–13]. As a result, esophagectomy is typically recom-
mended for T1b disease, whereas T1a disease may be trea-
ted by endoscopic resection [14]. It is therefore important
to differentiate between these two T stages. Radiology
imaging with computed tomography and magnetic reso-
nance imaging are unable to differentiate between these
two T stages and thus endoscopic ultrasound has been
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cancers [14].
Recently literature has questioned the accuracy of EUS in
staging of early esophageal cancer. Young and colleagues
systematically reviewed studies comparing EUS staging to
definitive EMR or surgery specimens of superficial esopha-
geal cancer and high grade dysplasia in Barrett’s esophagus
[15]. They evaluated 12 studies (individual data from 132
patients). EUS correctly predicted the T stage with only 65%
accuracy. They concluded that pre-treatment EUS for HGD
or intramucosal esophageal adenocarcinoma is unnecessary
and might, in fact, be misleading [15]. Pouw et al. also per-
formed a retrospective analysis on patients at the Academic
Medical Center in the Netherlands with superficial esopha-
geal cancer, who had an EUS preceding an EMR. Of 131
patients, EUS found possible submucosal invasion
(T1b staging) in 26 (20%) [16]. However, in 14 of the
26 patients (54%) there was no submucosal invasion on
pathology. Per the authors, EUS did not add any informa-
tion compared to EMR.
More recently Thoasani et al. performed a systematic
review and meta-analysis comparing EUS staging to EMR
specimens or surgical specimens [14]. The authors took a
broader approach than the previously mentioned studies
by including esophageal squamous cell carcinoma and in-
cluding studies in languages other than English. Overall,
the study included 1019 patients from 19 studies. Their
group found that EUS correctly predicted the T stage in
84% of adenocarcinomas and in 81% of squamous cell
carcinomas.
Detection of lymph node involvement in esophageal
cancer is also a crucial issue and the accuracy of EUS
nodal staging has been compared to a variety of other ra-
diological techniques. A pooled summary by Polkowiski is
presented in Table 1 [17]. For regional lymph node metas-
tases, all tests had similar overall diagnostic performance:
however, the sensitivity of CT and FDG-PET was significantly
lower than that of EUS, whereas the specificity was signif-
icantly higher. In addition, a study by Shami et al. found
that about 20% of patients referred for EMR had lymph
node involvement on EUS and that EUS-FNA changed
course of management [18].
Overall, EUS in esophageal cancer staging is still rec-
ommended by authorities in the field. Heterogeneity
among studies are likely related to operator experience,
techniques of EUS employed (linear vs radial vs
high-frequency mini-probes) and location of tumors. In
our own practice, we use EUS to identify early-stage
disease (less than T2) for consideration of EMR. The
EMR specimen is then used as the definitive tissue stag-
ing. We also use EUS for nodal staging, when
cross-sectional imaging has failed to identify distant/met-
astatic disease.
GASTRIC CANCER STAGING WITH
EUS: DOES IT HELP DETERMINE
WHO NEEDS NEOADJUVANT
THERAPY AND IS IT BETTER THAN
CT IMAGING?
Unfortunately, outside of patients involved in gastric
cancer screening programs, the majority of patients diag-
nosed with gastric cancer have advanced disease at time of
presentation and are unable to have a curative resection
[19].
The purpose of clinical staging gastric cancer is to deter-
mine which patients have locoregional/resectable disease
versus systemic involvement. The only accepted criteria
for unresectable gastric cancer are the presence of distant
metastasis and invasion of major vessels such as the aorta
and celiac axis (including hepatic and proximal splenic ar-
teries) [20–21].
CT scan, EUS and MRI are all utilized for gastric cancer
staging and the method used is often dependent on local
expertise. At present, most experts still recommend EUS
as the first line for staging, as this technique historically
has had the greatest accuracy for both T and N staging.
With advances in cross-sectional imaging resolution and
technique, the accuracy of MRI and CT are now compa-
rable to EUS for gastric cancer staging. Studies directly
comparing these modalities are scarce [17, 22–24]. A
meta-analysis has indirectly compared all three modalities
and a summary of these results is listed in Table 2 [17].
Where local EUS availability is limited, CT scanning is a
reasonable method of staging and can yield comparable
results.
Table 1. Direct comparisons of endoscopic ultrasonography,
helical or multi-detector row computed tomography and pos-
itron emission tomography in the detection of lymph node
metastases from esophageal carcinoma. Data extracted from
six studies directly comparing EUS to helical or multi-detector
row CT and/or FDG-PET (regional and coeliac lymph nodes
combined). (Table used by permission of Elsevier.) Polkowski
M. Endoscopic staging of upper intestinal malignancy. Best
Practice & Research Clinical Gastroenterology 2009;23:649–
661 [17]
Test Pooled sensitivity Pooled specificity Pooled accuracy
(95% CI) (95% CI) (95% CI)
EUS-FNA 0.81 (0.76–0.85) 0.73 (0.63–0.80) 0.77 (0.72–0.81)
CT Scan 0.54 (0.48–0.61) 0.87 (0.79–0.92) 0.65 (0.60–0.70)
FDG-PET 0.52 (0.44–0.60) 0.82 (0.65–0.92) 0.69 (0.60–0.77)
CI=confidence interval, CT=computed tomography, EUS=endo-
scopic ultrasonography, FDG-PET=18F-fluorodeoxyglucose posi-
tron emission tomography
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gastric cancer is that it is considered operator-dependent
and under-staging of the primary gastric cancer does occur
[25–27]. Over-staging may also occur secondary to inflam-
mation surrounding the tumor. Most troublesome is distin-
guishing T2 tumors (invading muscularis propria) from T3
tumors (penetrating subserosal connective tissue without
invasion of visceral peritoneum or adjacent structures)
when applying the American Joint Committee on Cancer
(AJCC) staging system used in the western hemisphere
and in most Asian countries [25–31]. Errors in determining
depth of a lesion will affect surgical resectability criteria
and the decision to administer neoaduvant therapy [28].
Neoadjuvant therapy is recommended for patients with
T2 disease or above, or if lymph node involvement is sus-
pected. On the other hand, early gastric cancer (T1A dis-
ease) is potentially amenable to endoscopic removal [19].
Table 3 lists the diagnostic performance of endoscopic ul-
trasonography in loco-regional staging of gastric carcinoma
based on a meta-analysis of 22 studies [17]. Although the
sensitivities are high for all T stages, T2 staging is the least
accurate, while T3/T4 EUS staging is more accurate.
Further concern regarding endosonographic overstaging
of T2 cancers was demonstrated in a retrospective study
performed by Kutup et al. in which EUS and histopathology
findings were compared [32]. Their group reported that
only 19 of 37 T1/T2N0 cases were correctly classified by
EUS and those that were misclassified were over-staged
and sent for neoadjuvant treatment. In addition, errors
with over-staging nodal involvement occur because EUS
characteristics of benign versus malignant nodes may not
be reliable [17].
In cases where CT has failed to detect metastatic disease,
EUS can sometime provide evidence of more subtle meta-
static spread. In particular, malignant ascites, detected by
EUS near the left lobe of the liver, can be aspirated and sent
to cytology to prove metastasis [32]. In addition, EUS may
detect lesions in the left lobe of the liver missed by CT scan
in patients previously thought to be resectable. Although
EUS is helpful in this regard, it should not be used as the
sole diagnostic test to rule out metastatic disease [33].
In summary, for both esophageal and gastric cancer, we
generally recommend an ‘outside-in’ approach. Cross-
sectional imaging such as CT is a useful first step to rule
out distant/metastatic disease and may also be accurate
for T and N staging. For patients without metastatic or de-
finitive T4 staging on cross-sectional imaging, EUS can then
be recommended for additional T and N information.
DOES NEEDLE SIZE MATTER IN
ENDOSCOPIC ULTRASOUND-FINE
NEEDLE ASPIRATION OF SOLID
LESIONS?
Successful ultrasound-fine needle aspiration (EUS-FNA) di-
agnosis of pancreatic disease, including pancreatic cancer,
was first reported in 1992 [34]. Since then, the indications
for EUS-FNA have rapidly expanded and it is considered a
very safe method given its low complication rate of less
than 2% [35–38]. EUS-FNA is now routinely used for diag-
nosis of pancreatic masses, subepithelial gastric tumors,
esophageal cancer staging, left lobe liver lesions and even
adrenal lesions [39–42]. Choice of needle gauge for fine
needle aspiration is a key question facing endosonogra-
phers. Currently there are three sizes available: 19-gauge,
22-gauge and 25-gauge. The 19-gauge needle is the largest
of the three and thus may have the potential to yield the
largest quantity of tissue sample, but this may come with a
higher risk of bleeding [43].
Most currently available data compare 22-gauge needles
to 25-gauge needles and data are limited on the use of
19-gauge needles. There is good quality evidence from ran-
domized prospective trials to compare the sensitivity/speci-
ficity of different FNA needles in the diagnosis of
Table 2. Indirect comparison of diagnostic performance of
endoscopic ultrasonography, multi-detector row computed to-
mography and magnetic resonance imaging in the assessment
of gastric carcinoma T-stage, based on 23 studies of EUS, 6 of
CT scan and 3 on MRI. (Table used by permission of Elsevier.)
Polkowski M. Endoscopic staging of upper intestinal malig-
nancy. Best Practice & Research Clinical Gastroenterology
2009;23:649–661 [17]
Detection of serosal involvement
Test T-staging accuracy
median (range)
Sensitivity
median (range)
Specificity
median (range)
EUS 0.83 (0.65–0.92) 0.93 (0.78–1.00) 0.88 (0.68–1.00)
CT 0.83 (0.77–0.89) 0.88 (0.83–1.00) 0.94 (0.80–0.97)
MRI 0.73 (0.71–0.83) 0.92 (0.90–0.93) 0.97 (0.91–1.00)
Table 3. Diagnostic performance of endoscopic ultrasonogra-
phy in loco-regional staging of gastric carcinoma (based on a
meta-analysis of 22 studies (Table used by permission of
Elsevier.) Polkowski M. Endoscopic staging of upper intestinal
malignancy. Best Practice & Research Clinical Gastroenterology
2009;23:649–661 [17]
Tumor
Stage
Pooled sensitivity (95% CI) Pooled specificity (95% CI)
T1 0.88 (0.85–0.91) 1.00 (1.00–1.00)
T2 0.82 (0.78–0.86) 0.96 (0.94–0.97)
T3 0.90 (0.87–0.92) 0.95 (0.93–0.96)
T4 0.99 (0.97–1.00) 0.97 (0.96–0.98)
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clusions of these studies for other type of lesions, especially
subepithelial lesions of the upper GI tract.
The first evidence regarding needle size came out in
2009. In 2009, Siddiqui et al. performed a randomized, con-
trolled prospective study on 131 patients undergoing
EUS-FNA in 131 patients [43]. Sixty-four patients underwent
EUS-FNA with a 22-gauge needle and 67 underwent
EUS-FNA with a 25-gauge needle. Cytology was diagnostic
in 91.6% of patients and did not differ statistically between
the two groups. The two groups did not differ in location of
the mass, size of the mass, sex of the patients, use of antic-
oagulatants/NSAID or diagnosis of the lesion (e.g. adeno-
carcinoma, neuroendocrine tumor, negative diagnosis).
They found that the needle size did not make a difference
regarding a diagnosis. The number of passes attempted
was the same, with onsite cytology present for all cases.
There was no difference in ease of needle passage, need
to change scope positions secondary to the needle or
needle malfunction.
Also in 2009, Lee et al. published a study on 12 patients
who underwent EUS-FNA for pancreatic and peri-
pancreatic masses [44]. All patients had an FNA with a
25-gauge and a 22-gauge needle. Needle order was se-
lected randomly and two passes were taken with each
needle. Samples were read immediately after the FNA by
cytopathologists, who were blinded to the needle used.
A diagnosis was made in all cases by both sizes of needles.
There was no difference in the cellularity of the samples
obtained between the needles.
In 2011, Fabbri et al. published a similar study than Lee
et al., with a total of 50 patients [45]. All patients had pan-
creatic masses and underwent EUS-FNA with both 25-gauge
and 22-gauge needles. The results were similar to Lee et al.,
showing that both needles statistically had the same diag-
nostic accuracy, with a trend for the 25-gauge needle to
yield a better cytologic diagnosis. Diagnostic accuracy was
94% with the 25-gauge needle and 84% with the 22-gauge
needle.
In 2010, Song et al. published a randomized, controlled
trial comparing 19-gauge and 22-gauge needles during
EUS-FNA in patients with pancreatic or peri-pancreatic
masses [46]. A total of 177 patients were enrolled: 60 in
the 19-gauge group and 57 in the 22-gauge group. Slides
of samples were made by endosonographers and retrospec-
tively reviewed by a cytopathologist, who was blinded to
the needle being used. Of note, the endoscopist was not
blinded, as the needle design is different between a
19-gauge and 22-gauge. Per study protocol, the groups
were allowed to change over to the other needle size if
the initial needle yielded a non-diagnostic result or there
was a technical failure. The diagnostic accuracy per inten-
tion- to-treat analysis was similar (19G: 86.7% vs 22G:
78.9% P=0.268). However when evaluating cases by a per
protocol basis the 19-gauge group contained a higher suc-
cess rate (93.9% versus 78.9%, P=0.006). The specimen cel-
lularity was higher in the 19-gauge group (P=0.033). In
addition the 19-gauge needle yielded better results in
body/tail lesions than the 22-gauge needle (95% versus
76.7%, P=0.031). Finally technical success, as defined by
successful needle passage and specimen adequacy, was
higher in the 19-gauge needle group vs the 22-gauge
needle group (93.9% versus 78.1%,, P=0.006). There were
12 cases where the 22-gauge needle could not yield suffi-
cient tissue to make a diagnosis. The 19-gauge needle was
able to make a diagnosis in 11 of these 12 patients. There
were five cases in the 19-gauge needle group in which tech-
nical failure was observed, because of mass location in the
head of the pancreas. Masses in the head of the pancreas
require the echoendoscope to be in the duodenum for sam-
pling and the scope is more angulated, making passing the
stiffer 19-gauge needle harder. There were no significant
complications in either group. This study concludes that the
19-gauge needle may yield more material and may be the
preferred choice for pancreatic lesions in the body/tail of
the pancreas, where the echoendoscope position is fairly
straight and passage of the 19-gauge needle is feasible.
Limitations to the Song et al. study have been expressed
in a published editorial [47]. First, there was reliance on
gross slide examination made by endosonographers,
where most studies have an on-site cytologist. In addition,
a mean of less than three passes were made from each
needle. Previous studies have advocated at least five
passes if no on-site cytologist is available. Finally, in the
experienced hands of the endosonographers in this study,
there were five failures in patients with pancreatic head
masses in the 19-gauge needle group and none in the
22-gauge needle group. Thus less-experienced endosono-
graphers must be cautious with the larger 19-gauge
needle, given the technical difficulty of passing this
needle in certain positions.
Camellini et al. published a 2011 study which random-
ized 129 patients with various GI lesions to EUS-FNA with
either a 25-gauge or 22-gauge needle [48]. Their design
was a crossover design similar to Song et al. This study in-
cluded lymph nodes and subepithelial upper GI lesions in
addition to pancreatic masses, although the majority of pa-
tients (84 of 129) had pancreatic masses. Their results were
similar to Siddiqui et al. in that there was no difference
between the 25-gauge or 22-gauge needles in terms of ad-
equacy of samples or number of passes required. There was
an advantage for the 25-gauge needle for pancreatic le-
sions in the uncinate process as a crossover to the
25-gauge needle was successfully performed in four pan-
creatic masses in the uncinate process.
A recent meta-analysis was published that included the
aforementioned studies, as well as six additional studies
that were retrospective or prospective and not randomized
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dles confer an advantage in tissue adequacy relative to
22-gauge, with no difference in diagnostic accuracy,
number of passes, or complications. They found that
there was limited data available regarding 19-gauge nee-
dles but the available data did not show evidence of im-
proved outcomes with these devices.
In summary, currently available evidence supports the
use of the smaller 25-gauge needle, which yields at least
comparable results to the 22-gauge and 19-gauge needles
and may be easier to maneuver, especially in locations
where an angulated echoendoscope is needed. There are
no convincing safety data showing any significant advan-
tage between the three commonly used FNA needle
gauges but it seems intuitive that a smaller needle that is
easier to maneuver would lead to fewer complications over
time. It should also be noted that needle size is only one
aspect of successful EUS-FNA. Factors not taken into
account in studies are skill of the endoscopist, use of the sty-
let and degree of needle suction and biopsy technique [50].
DOES THE STYLET AID OR HINDER
EUS ASSISTED FINE NEEDLE
ASPIRATION?
Fine needle aspiration during EUS is traditionally per-
formed with a stylet in the needle. Once the needle is
inside the target tissue, the stylet is first pushed forward
slightly, to expel any needle tract tissue, and then removed
from the needle. It is thought the stylet helps prevent con-
tamination of normal gastrointestinal tract cells.
Recently it has come into question whether the stylet is
necessary for accurate tissue diagnosis. Rastogi et al. per-
formed a randomized, prospective trial on 118 patients
who underwent EUS-FNA with a 22-gauge needle [51].
Each patient underwent two FNA passes with a stylet and
two passes without. The order of the passes was random-
ized. The lesions were pancreatic masses (n=61), lymph
nodes (n=31), liver lesions (n=6), left adrenal (n=5) and
other lesions (n=15). The cytopathologist was blinded to
the results. The outcomes measured were degree of cellu-
larity, adequacy, contamination, amount of blood and the
diagnostic yield of malignancy. The investigators found no
difference in quality of specimen or diagnostic yield with or
without a stylet.
Sahai et al. performed a similar prospective study to
Rastogi et al. on 135 lesions with a 22-gauge needle [52].
Fifty-eight percent of the lesions were masses (the majority
pancreatic masses) and 42% lymph nodes. The use of the
stylet was randomized in a 1:2 ratio. This study showed that
the stylet did not increase the yield for malignant cells and
was in fact associated with poorer sample quality. The
authors concluded that the use of the stylet is questionable
and requires further investigation.
Wani et al. performed a prospective study with 100 pa-
tients who underwent EUS-FNA with either a 25-gauge or
22-gauge needle [53]. The number of passes was predeter-
mined by the type of lesion. The order of the passes, with or
without the stylet, was randomized. The same outcomes
were measured as Rastogi et al. These investigators also
confirmed no difference in yield and the study was termi-
nated at interim analysis. The presence of a stylet made no
difference overall, nor in per lesion analysis, in regards to
degree of cellularity, adequacy, contamination, amount of
blood and the diagnostic yield of malignancy. Wani et al.
also performed a retrospective case-controlled study that
included 228 lesions [54]. Again, the stylet was not shown
to make a difference with regards to the before-mentioned
end points.
There is considerable evidence, three prospective ran-
domized trials and one retrospective trial, supporting the
notion that the stylet does not aid in the sampling for fine
needle aspiration; in fact one study showed it may hinder
obtaining quality samples. Although larger trials may be
needed prior to a consensus, we conclude that it is reason-
able not to use the stylet for EUS-FNA in most
circumstances.
CONTRAST-ENHANCED HARMONIC
EUS: A FANCY TOOL OR REAL LIFE
APPLICATION?
Contrast-enhanced harmonic EUS (CEH-EUS) has been de-
veloped to allow detection of microvascular patterns of le-
sions that could potentially help differentiate malignant
from benign disease. It is important to note that per the
European literature, CEH-EUS is not indicated for the de-
tection of lesions, but for characterization of lesions al-
ready detected by conventional imaging [55].
In CEH-EUS, an intravenous contrast agent is injected
that contains microbubbles. On exposure to the ultrasound
pulse, these microbubbles oscillate and the transducer is
able to detect signals from the microbubbles in vessels, al-
lowing visualization of the parenchymal microvascularture
[55–57]. There are three main patterns of vascular enhance-
ment: ‘no enhancement’, ‘homogeneous enhancement/
hyperenhacement’ and ‘heterogeneous enhancement’ [58].
One the most useful potential applications for CEH-EUS is
in the diagnosis of adenocarcinoma of the pancreas.
Contrast enhancement of the pancreas is seen soon after
enhancement of the aorta. The enhancement of the mass
in question is compared to the surrounding parenchyma.
Early studies suggest that, in 90% of adenocarcinoma
of the pancreas, the lesion is found to be hypoenhancing
on CEH-EUS (Figure 1)[ 56]. In addition CEH-EUS may help
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and thus could potentially serve as a useful assessment of
response to therapy response to therapy [59].
Perhaps one of the most challenging diagnostic clinical
scenarios is differentiating between benign and malignant
disease in ‘mass-forming’ acute, chronic and autoimmune
pancreatitis (AIP) [60–63]. Mass-forming pancreatitis and
autoimmune pancreatitis have similar enhancement to
normal pancreas parenchyma on CEH-EUS, where adeno-
carcinoma is hypoenhancing. These differing imaging char-
acteristics could prove especially useful to help confirm a
‘negative’ FNA during evaluation of a pancreatic mass.
CEH-EUS may also distinguish neuroendocrine tumors
from adenocarcinoma [56, 64, 65]. Standard EUS can al-
ready detect small NET lesions that may not be seen on
CT scan. CEH-EUS may provide additional information,
given the hypervascular nature of the NET vs adenocarci-
noma (Figure 2)[ 56].
CEH-EUS may also aid in the diagnosis of pancreatic cystic
lesions [67–68]. Minute microcystic lesions can sometimes
mimic solid lesions on conventional EUS. However, on
CEH-EUS, these cystic lesions hyperenhance, given their vas-
cularity. In contrast, pseudo-cysts contain non-vascular
debris after their early stages and do not enhance on
CEH-EUS.
Finally, an additional potential application for CEH-EUS is
in determining the malignant potential of gastrointestinal
stromal tumors. 10–30% of GIST lesions are malignant:
however preoperative tools to determine malignant poten-
tial are not optimal [69]. Obtaining EUS-FNA samples of
sufficient cellularity is often challenging. Sakamoto et al.
conducted a study in 76 consecutive patients who under-
went EUS-FNA and CEH-EUS for subepithelial lesions [69].
Twenty-nine patients underwent surgical resection and this
group was divided into high versus low malignant poten-
tial. The ability of EUS-FNA and CEH-EUS to predict
high-grade malignancy in GIST was then compared.
CEH-EUS identified irregular vessels and predicted
high-grade GIST malignancies with a sensitivity, specificity
and accuracy of 100, 63 and 83%, respectively. EUS-FNA
had a sensitivity, specificity and accuracy of 63, 92 and
81%, respectively.
Figure 1. No enhancement of the mass vascularisation with periphericeal hypervascularisation after contrast injection: CE-EUS
image of pancreatic adenocarcinoma. (Reproduced by permission of Elsevier.)
Figure 2. EUS aspects of endocrine tumor of the pancreas. Enhancement of the micro-vascularisation after contrast injection.
(Reproduced by permission of Elsevier.)
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The field of diagnostic and therapeutic EUS is rapidly evolv-
ing. Recently published work is already helping to clarify
some of the important controversies involving the role of
EUS in cancer staging and diagnosis, as described in this
review. We expect that many of the questions to be de-
bated and clarified in the near future of EUS will pertain
to a variety of therapeutic applications of this technique.
Of particular interest is the emerging role of EUS-guided
biliary access techniques (vs standard percutaneous
approaches) for scenarios in which ERCP is not feasible.
EUS-guided intra-tumoral therapy (including drug delivery
and thermal ablation techniques) and EUS-guided manage-
ment of variceal bleeding are additional topics of great in-
terest, for which the appropriate role of EUS will need to be
thoughtfully investigated.
Along with this growth come controversial issues. In this
review we discussed five controversial topics in endoscopic
ultrasound. Although the outcomes of endoscopic ultra-
sound are highly user-dependent and have their limita-
tions, we have shown literature to support its beneficial
use in esophageal and gastric cancer staging. In addition,
since its first use in the 1980s, we are still learning which
techniques are optimal for fine needle aspiration in aiding
diagnosis. Two of the common issues regarding needle size
and stylet use were presented in this review. More data is
probably needed until we have characterized the correct
needle size for fine needle aspiration. Factors related to
choosing the correct needle correspond to the type and
location of the lesion. We briefly discussed the role of the
stylet and whether it has a role in fine needle aspiration.
Current data suggests that the stylet may not be an essen-
tial component of fine needle aspiration. Finally new tech-
niques in EUS are emerging and will likely have a niche in
aiding diagnosis of difficult-to-characterize lesions. In this
review we have discussed the role of contrast-enhanced
harmonic EUS. This technique is evolving and will likely
play a key role in diagnostic EUS in the future.
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